​

TC Biopharm Stock (NASDAQ:TCBP)

OwnershipFinancialsChart
TC Biopharm by TradingView

Previous Close

$0.66

52W Range

$0.44 - $41.50

50D Avg

$1.56

200D Avg

$7.78

Market Cap

$6.53M

Avg Vol (3M)

$1.67M

Beta

0.25

Div Yield

-

TCBP Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

41

IPO Date

Feb 11, 2022

Website

TCBP Performance

TCBP Financial Summary

Dec 23Dec 22Dec 21
Revenue-$3.84M$1.98M
Operating Income$-14.24M$-12.06M$-7.28M
Net Income$-5.91M$-1.39M$-13.58M
EBITDA$-14.24M$-11.09M$-6.26M
Basic EPS$-0.96$-2.02$-34.76
Diluted EPS$-0.96$-2.02$-34.73

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
ICUSeaStar Medical Holding Corporation
ZVSAZyVersa Therapeutics, Inc.
PHIOPhio Pharmaceuticals Corp.
REVBRevelation Biosciences, Inc.
RNAZTransCode Therapeutics, Inc.
BDRXBiodexa Pharmaceuticals Plc
QNRXQuoin Pharmaceuticals, Ltd.
VRAXVirax Biolabs Group Limited
IMMXImmix Biopharma, Inc.
ALLRAllarity Therapeutics, Inc.
ZURAZura Bio Limited
SONNSonnet BioTherapeutics Holdings, Inc.
UNCYUnicycive Therapeutics, Inc.
PALIPalisade Bio, Inc.